The estimated Net Worth of Jeffrey W Jacobs is at least $1.07 millió dollars as of 22 November 2021. Mr Jacobs owns over 5,754 units of Ardelyx Inc stock worth over $712,119 and over the last 10 years he sold ARDX stock worth over $353,470.
Mr has made over 21 trades of the Ardelyx Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 5,754 units of ARDX stock worth $5,639 on 22 November 2021.
The largest trade he's ever made was selling 50,804 units of Ardelyx Inc stock on 15 September 2020 worth over $286,027. On average, Mr trades about 4,681 units every 96 days since 2015. As of 22 November 2021 he still owns at least 119,483 units of Ardelyx Inc stock.
You can see the complete history of Mr Jacobs stock trades at the bottom of the page.
Jeffrey W. Jacobs is the Chief Scientific Officer at Ardelyx Inc.
Mr Jacobs is 57, he's been the Chief Scientific Officer of Ardelyx Inc since . There are 6 older and 11 younger executives at Ardelyx Inc. The oldest executive at Ardelyx Inc is Gordon Ringold, 69, who is the Independent Director.
Jeffrey's mailing address filed with the SEC is C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT, CA, 94555.
Over the last 10 years, insiders at Ardelyx Inc have traded over $37,312,621 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871 . The most active insiders traders include Forest Baskett, Scott D Sandell és Anthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $1,784,764. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth $46,650.
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Ardelyx Inc executives and other stock owners filed with the SEC include: